Literature DB >> 32339239

One Step Further Toward Defining the Exceptional Cancer Responder.

James M Ford1, Beverly S Mitchell2.   

Abstract

Entities:  

Year:  2021        PMID: 32339239      PMCID: PMC7781456          DOI: 10.1093/jnci/djaa062

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  8 in total

1.  Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.

Authors:  Dung T Le; Jennifer N Durham; Kellie N Smith; Hao Wang; Bjarne R Bartlett; Laveet K Aulakh; Steve Lu; Holly Kemberling; Cara Wilt; Brandon S Luber; Fay Wong; Nilofer S Azad; Agnieszka A Rucki; Dan Laheru; Ross Donehower; Atif Zaheer; George A Fisher; Todd S Crocenzi; James J Lee; Tim F Greten; Austin G Duffy; Kristen K Ciombor; Aleksandra D Eyring; Bao H Lam; Andrew Joe; S Peter Kang; Matthias Holdhoff; Ludmila Danilova; Leslie Cope; Christian Meyer; Shibin Zhou; Richard M Goldberg; Deborah K Armstrong; Katherine M Bever; Amanda N Fader; Janis Taube; Franck Housseau; David Spetzler; Nianqing Xiao; Drew M Pardoll; Nickolas Papadopoulos; Kenneth W Kinzler; James R Eshleman; Bert Vogelstein; Robert A Anders; Luis A Diaz
Journal:  Science       Date:  2017-06-08       Impact factor: 47.728

2.  Genome sequencing identifies a basis for everolimus sensitivity.

Authors:  Gopa Iyer; Aphrothiti J Hanrahan; Matthew I Milowsky; Hikmat Al-Ahmadie; Sasinya N Scott; Manickam Janakiraman; Mono Pirun; Chris Sander; Nicholas D Socci; Irina Ostrovnaya; Agnes Viale; Adriana Heguy; Luke Peng; Timothy A Chan; Bernard Bochner; Dean F Bajorin; Michael F Berger; Barry S Taylor; David B Solit
Journal:  Science       Date:  2012-08-23       Impact factor: 47.728

3.  Phase II study of everolimus in metastatic urothelial cancer.

Authors:  Matthew I Milowsky; Gopa Iyer; Ashley M Regazzi; Hikmat Al-Ahmadie; Scott R Gerst; Irina Ostrovnaya; Lan L Gellert; Rana Kaplan; Ilana R Garcia-Grossman; Deepa Pendse; Arjun V Balar; Anne Marie Flaherty; Alisa Trout; David B Solit; Dean F Bajorin
Journal:  BJU Int       Date:  2013-04-03       Impact factor: 5.588

4.  Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.

Authors:  Talia Golan; Pascal Hammel; Michele Reni; Eric Van Cutsem; Teresa Macarulla; Michael J Hall; Joon-Oh Park; Daniel Hochhauser; Dirk Arnold; Do-Youn Oh; Anke Reinacher-Schick; Giampaolo Tortora; Hana Algül; Eileen M O'Reilly; David McGuinness; Karen Y Cui; Katia Schlienger; Gershon Y Locker; Hedy L Kindler
Journal:  N Engl J Med       Date:  2019-06-02       Impact factor: 91.245

Review 5.  Going to extremes: determinants of extraordinary response and survival in patients with cancer.

Authors:  Flurina A M Saner; Alan Herschtal; Brad H Nelson; Anna deFazio; Ellen L Goode; Susan J Ramus; Ahwan Pandey; Jessica A Beach; Sian Fereday; Andrew Berchuck; Stephanie Lheureux; Celeste Leigh Pearce; Paul D Pharoah; Malcolm C Pike; Dale W Garsed; David D L Bowtell
Journal:  Nat Rev Cancer       Date:  2019-06       Impact factor: 60.716

6.  Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.

Authors:  Joaquin Mateo; Nuria Porta; Diletta Bianchini; Ursula McGovern; Tony Elliott; Robert Jones; Isabel Syndikus; Christy Ralph; Suneil Jain; Mohini Varughese; Omi Parikh; Simon Crabb; Angus Robinson; Duncan McLaren; Alison Birtle; Jacob Tanguay; Susana Miranda; Ines Figueiredo; George Seed; Claudia Bertan; Penny Flohr; Berni Ebbs; Pasquale Rescigno; Gemma Fowler; Ana Ferreira; Ruth Riisnaes; Rita Pereira; Andra Curcean; Robert Chandler; Matthew Clarke; Bora Gurel; Mateus Crespo; Daniel Nava Rodrigues; Shahneen Sandhu; Aude Espinasse; Peter Chatfield; Nina Tunariu; Wei Yuan; Emma Hall; Suzanne Carreira; Johann S de Bono
Journal:  Lancet Oncol       Date:  2019-12-02       Impact factor: 41.316

7.  Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.

Authors:  Colin C Pritchard; Joaquin Mateo; Michael F Walsh; Navonil De Sarkar; Wassim Abida; Himisha Beltran; Andrea Garofalo; Roman Gulati; Suzanne Carreira; Rosalind Eeles; Olivier Elemento; Mark A Rubin; Dan Robinson; Robert Lonigro; Maha Hussain; Arul Chinnaiyan; Jake Vinson; Julie Filipenko; Levi Garraway; Mary-Ellen Taplin; Saud AlDubayan; G Celine Han; Mallory Beightol; Colm Morrissey; Belinda Nghiem; Heather H Cheng; Bruce Montgomery; Tom Walsh; Silvia Casadei; Michael Berger; Liying Zhang; Ahmet Zehir; Joseph Vijai; Howard I Scher; Charles Sawyers; Nikolaus Schultz; Philip W Kantoff; David Solit; Mark Robson; Eliezer M Van Allen; Kenneth Offit; Johann de Bono; Peter S Nelson
Journal:  N Engl J Med       Date:  2016-07-06       Impact factor: 91.245

8.  The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study.

Authors:  Barbara A Conley; Lou Staudt; Naoko Takebe; David A Wheeler; Linghua Wang; Maria F Cardenas; Viktoriya Korchina; Jean Claude Zenklusen; Lisa M McShane; James V Tricoli; Paul M Williams; Irina Lubensky; Geraldine O'Sullivan-Coyne; Elise Kohn; Richard F Little; Jeffrey White; Shakun Malik; Lyndsay N Harris; Bhupinder Mann; Carol Weil; Roy Tarnuzzer; Chris Karlovich; Brian Rodgers; Lalitha Shankar; Paula M Jacobs; Tracy Nolan; Sean M Berryman; Julie Gastier-Foster; Jay Bowen; Kristen Leraas; Hui Shen; Peter W Laird; Manel Esteller; Vincent Miller; Adrienne Johnson; Elijah F Edmondson; Thomas J Giordano; Benjamin Kim; S Percy Ivy
Journal:  J Natl Cancer Inst       Date:  2021-01-04       Impact factor: 11.816

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.